Due to inadequate disclosure policies, drug company payments to European researchers and institutions for R&D work are often opaque, raising concerns about conflicts of interest and industry justifications for high medicine prices, according to a new study.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
